Side-by-side · Research reference
GHRP-2vsSemax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed15/42 cited
BHuman-MechanisticDraft12/39 cited
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
Semax
Cognitive enhancer · Russian Pharma
Intranasal · 2–3×/day during cognitive demand
01Mechanism of Action
Parameter
GHRP-2
Semax
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
Yes, with somatostatin feedback active
—
Origin
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-2
Semax
Frequency
1–3× per day
2–3× per day during cognitive demand
Lower / starter dose
50 mcg per dose
100 mcg / dose
Evidence basis
Phase 2 + clinical diagnostic useBowers 1990
Human-mechanistic + Russian clinicalKaplan 2017
Duration
8–12 weeks on / 4 off (anecdotal)
10–14 day cycles, repeated PRN
Reconstitution
Bacteriostatic water
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
Pre-sleep + fasted preferred
Morning + early afternoon
04Side Effects & Safety
Parameter
GHRP-2
Semax
Prolactin elevation
Mild but measurable
—
Hunger
Strong appetite increase
—
Injection site reaction
Mild erythema
—
IGF-1 elevation
Strong; monitor with chronic high-dose use
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Avoid
Nasal irritation
—
Mild burning or congestion (transient)
Sleep disruption
—
Late-day dosing may interfere with sleep
Headache
—
Uncommon, transient
Long-term safety
—
Limited Western RCT data
Absolute Contraindications
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Semax
- ·Pregnancy / breastfeeding
Relative Contraindications
GHRP-2
- ·Untreated diabetes
Semax
- ·Active psychiatric instability
- ·Concurrent strong stimulants
05Administration Protocol
Parameter
GHRP-2
Semax
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
SQ — abdomen or thigh. Rotate sites.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
Pre-sleep + fasted preferred.
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Refrigerate after reconstitution; light-protected.
5. Needle
29–31G, 4–8 mm insulin syringe.
Cycle on/off to avoid neurochemical adaptation.
06Stack Synergy
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition
Semax
+ Selank
ModerateSemax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.
- Semax
- 200–600 mcg intranasal · morning + afternoon
- Selank
- 150–300 mcg intranasal · midday + early evening
- Primary benefit
- Cognitive enhancement + stress mitigation